171 related articles for article (PubMed ID: 25542926)
1. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
Ann Oncol; 2015 Apr; 26(4):688-695. PubMed ID: 25542926
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
[TBL] [Abstract][Full Text] [Related]
3. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
[TBL] [Abstract][Full Text] [Related]
5. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
6. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
7. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis.
Wu T; Tong Z; Ren T; Xie D; Sun X
Clin Exp Med; 2023 Sep; 23(5):1501-1513. PubMed ID: 36315312
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.
Glaspy J; Crawford J; Vansteenkiste J; Henry D; Rao S; Bowers P; Berlin JA; Tomita D; Bridges K; Ludwig H
Br J Cancer; 2010 Jan; 102(2):301-15. PubMed ID: 20051958
[TBL] [Abstract][Full Text] [Related]
13. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.
Lai Y; Palazzo JP; Cristofanilli M; Hyslop T; Civan J; Avery T; Myers RE; Li B; Ye Z; Xing J; Yang H
Breast Cancer Res Treat; 2014 Nov; 148(1):175-85. PubMed ID: 25261294
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
[TBL] [Abstract][Full Text] [Related]
16. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
18. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
J Clin Oncol; 2019 May; 37(15):1336-1351. PubMed ID: 30969847
[TBL] [Abstract][Full Text] [Related]
19. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis.
Hedenus M; Osterborg A; Tomita D; Bohac C; Coiffier B
Leuk Lymphoma; 2012 Nov; 53(11):2151-8. PubMed ID: 22497574
[TBL] [Abstract][Full Text] [Related]
20. End of an era for erythropoiesis-stimulating agents in oncology.
Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
